Pediatric Drugs

Papers
(The H4-Index of Pediatric Drugs is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Diagnosis of Serious Conditions Delayed in Association with Ondansetron Treatment for Vomiting in the Pediatric Emergency Department88
Alirocumab: Pediatric First Approval76
Treatment Options for Alopecia Areata in Children and Adolescents62
Pharmacogenetic Aspects of Drug Metabolizing Enzymes and Transporters in Pediatric Medicine: Study Progress, Clinical Practice and Future Perspectives52
Optimizing Drug Selection in Children with Multiple Sclerosis: What Do We Know and What Remains Unanswered?52
Gentamicin Pharmacokinetics in Neonates Undergoing Therapeutic Hypothermia for Hypoxic Ischemic Encephalopathy48
Acknowledgement to Referees45
Perioperative Indications for Gabapentinoids in Pediatrics: A Narrative Review37
Recent Advances in the Management of Seizures in Children32
Managing Lupus Nephritis in Children and Adolescents28
A New Perspective on Drugs for Duchenne Muscular Dystrophy: Proposals for Better Respiratory Outcomes and Improved Regulatory Pathways24
Guselkumab: Pediatric First Approval24
Puzolcabtagene Autoleucel: Pediatric First Approval24
History and Current Status of Growth Hormone Treatment in Children23
Vedolizumab Versus Other Biologics and the Risk of Venous Thromboembolism in Patients with Pediatric-Onset Inflammatory Bowel Diseases: A Target Trial Emulation Study22
Commercial Versus Compounded Preparations in Pediatric Ophthalmology22
Acute Phase Reaction After First Neridronate Infusion in Children with Osteogenesis Imperfecta: An Analysis Based on Questionnaire Data from 65 Patients21
Intranasal Analgesia in Preterm and Term Neonates19
Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study19
0.023812055587769